27838489|t|Hypoxia / reoxygenation -induced HMGB1 translocation and release promotes islet proinflammatory cytokine production and early islet graft failure through TLRs signaling
27838489|a|High-mobility group box 1 (HMGB1) translocation and release, which is involved in several tissue types of ischemia-reperfusion injuries, activate innate immunity by inducing proinflammatory cytokine production through its interaction with toll-like receptors (TLRs). Our objective was to determine the role of HMGB1 and the degree of activation of TLR -related signal transduction pathways in hypoxia / reoxygenation (H / R)-induced proinflammatory cytokine production and intra-islet graft inflammation. After islets are exposed to hypoxia - reoxygenation for 24h, TLR2 / 4 expression and TLR -mediated signaling was up-regulated in islets, and HMGB1 was translocated from the nucleus to the cytoplasm and released to the extracellular space. With H / R exposure, proinflammatory cytokine production (IL-1β and TNF-α) and islet injury were significantly increased, and these effects depend on TLR2 / 4 signaling pathways. Exogenous HMGB1 also induces islet inflammation and increases the phosphorylation of STAT3, p38 and IκBα in wild-type islets. TLR2 deficiency in TLR2 - KO islets resulted in the inhibition of IL-1β production and STAT3 / p38 phosphorylation after HMGB1 exposure. TLR4 deficiency in TLR4 - KO islets resulted in the inhibition of TNF-α production and IκBα phosphorylation after HMGB1 exposure. Pre-incubation of the STAT3, p38, or NF-κB inhibitors significantly inhibited HMGB1 -induced IL-1β or TNF-α production in islets, but the effect of HMGB1 or H / R -induced islet injury was not counteracted by a separate treatment of the STAT3 inhibitor, p38 inhibitor, or NF-κB inhibitors. HMGB1 inhibition by ethyl pyruvate or blockade by neutralizing antibodies significantly decreased the phosphorylation of STAT3, p38 and IκBα, the production of IL-1β and TNF-α, and the islet injury in wild-type islets after exposure to H / R and significantly improved early islet graft failure. Thus, our results suggest that HMGB1 released from H / R induced islets works in an autocrine manner to up-regulate STAT or p38 and augment IL-1β production via TLR2, and up-regulate NF-κB and augment TNF-α production via TLR4 in intra-islet, which are associated with H / R -induced islet injury and early graft failure.
27838489	0	7	Hypoxia	T046	C0242184
27838489	10	23	reoxygenation	T061	C0087111
27838489	33	38	HMGB1	T116,T123	C0019796
27838489	39	52	translocation	T043	C0599893
27838489	57	64	release	T169	C0391871
27838489	74	79	islet	T023	C0022131
27838489	80	115	proinflammatory cytokine production	T040	C1327413
27838489	120	125	early	T079	C1279919
27838489	126	131	islet	T023	C0022131
27838489	132	145	graft failure	T046	C1262018
27838489	154	158	TLRs	T116,T192	C0670896
27838489	159	168	signaling	T044	C1514762
27838489	169	194	High-mobility group box 1	T116,T123	C0019796
27838489	196	201	HMGB1	T116,T123	C0019796
27838489	203	216	translocation	T043	C0599893
27838489	221	228	release	T169	C0391871
27838489	259	265	tissue	T024	C0040300
27838489	275	304	ischemia-reperfusion injuries	T037	C0035126
27838489	315	330	innate immunity	T032	C0020969
27838489	343	378	proinflammatory cytokine production	T040	C1327413
27838489	391	402	interaction	T169	C1704675
27838489	408	427	toll-like receptors	T116,T192	C0670896
27838489	429	433	TLRs	T116,T192	C0670896
27838489	479	484	HMGB1	T116,T123	C0019796
27838489	503	513	activation	T052	C1879547
27838489	517	520	TLR	T116,T192	C0670896
27838489	530	558	signal transduction pathways	T044	C0086982
27838489	562	569	hypoxia	T046	C0242184
27838489	572	585	reoxygenation	T061	C0087111
27838489	587	588	H	T046	C0242184
27838489	591	592	R	T061	C0087111
27838489	602	637	proinflammatory cytokine production	T040	C1327413
27838489	642	653	intra-islet	T023	C0022131
27838489	654	659	graft	T122	C0181074
27838489	660	672	inflammation	T046	C0021368
27838489	680	686	islets	T023	C0022131
27838489	691	698	exposed	T080	C0332157
27838489	702	709	hypoxia	T046	C0242184
27838489	712	725	reoxygenation	T061	C0087111
27838489	735	739	TLR2	T116,T192	C0754728
27838489	742	743	4	T116,T192	C1411976
27838489	744	754	expression	T045	C1171362
27838489	759	762	TLR	T116,T192	C0670896
27838489	773	782	signaling	T044	C1514762
27838489	787	799	up-regulated	T044	C0041904
27838489	803	809	islets	T023	C0022131
27838489	815	820	HMGB1	T116,T123	C0019796
27838489	825	837	translocated	T043	C0599893
27838489	847	854	nucleus	T026	C0007610
27838489	862	871	cytoplasm	T026	C0010834
27838489	876	884	released	T169	C0391871
27838489	892	911	extracellular space	T030	C0015352
27838489	918	919	H	T046	C0242184
27838489	922	923	R	T061	C0087111
27838489	924	932	exposure	T080	C0332157
27838489	934	969	proinflammatory cytokine production	T040	C1327413
27838489	971	976	IL-1β	T116,T129	C0021753
27838489	981	986	TNF-α	T116,T129	C1456820
27838489	992	997	islet	T023	C0022131
27838489	998	1004	injury	T037	C0178314
27838489	1063	1067	TLR2	T116,T192	C0754728
27838489	1070	1071	4	T116,T192	C1411976
27838489	1072	1090	signaling pathways	T044	C0037080
27838489	1102	1107	HMGB1	T116,T123	C0019796
27838489	1121	1126	islet	T023	C0022131
27838489	1127	1139	inflammation	T046	C0021368
27838489	1158	1173	phosphorylation	T044	C1158886
27838489	1177	1182	STAT3	T116,T123	C0253050
27838489	1184	1187	p38	T116,T126	C1120843
27838489	1192	1196	IκBα	T116,T123	C0126732
27838489	1210	1216	islets	T023	C0022131
27838489	1218	1222	TLR2	T116,T192	C0754728
27838489	1223	1233	deficiency	T169	C0011155
27838489	1237	1241	TLR2	T028	C1336634
27838489	1244	1246	KO	T063	C0599772
27838489	1247	1253	islets	T023	C0022131
27838489	1270	1280	inhibition	T052	C3463820
27838489	1284	1289	IL-1β	T116,T129	C0021753
27838489	1290	1300	production	T044	C0597295
27838489	1305	1310	STAT3	T116,T123	C0253050
27838489	1313	1316	p38	T116,T126	C1120843
27838489	1317	1332	phosphorylation	T044	C1158886
27838489	1339	1344	HMGB1	T116,T123	C0019796
27838489	1345	1353	exposure	T080	C0332157
27838489	1355	1359	TLR4	T116,T192	C1411976
27838489	1360	1370	deficiency	T169	C0011155
27838489	1374	1378	TLR4	T028	C1336636
27838489	1381	1383	KO	T063	C0599772
27838489	1384	1390	islets	T023	C0022131
27838489	1407	1417	inhibition	T052	C3463820
27838489	1421	1426	TNF-α	T116,T129	C1456820
27838489	1427	1437	production	T044	C0597295
27838489	1442	1446	IκBα	T116,T123	C0126732
27838489	1447	1462	phosphorylation	T044	C1158886
27838489	1469	1474	HMGB1	T116,T123	C0019796
27838489	1475	1483	exposure	T080	C0332157
27838489	1485	1499	Pre-incubation	T059	C0022885
27838489	1507	1512	STAT3	T116,T123	C0253050
27838489	1514	1517	p38	T116,T126	C1120843
27838489	1522	1527	NF-κB	T116,T129	C0079904
27838489	1553	1562	inhibited	T052	C3463820
27838489	1563	1568	HMGB1	T116,T123	C0019796
27838489	1578	1583	IL-1β	T116,T129	C0021753
27838489	1587	1592	TNF-α	T116,T129	C1456820
27838489	1593	1603	production	T044	C0597295
27838489	1607	1613	islets	T023	C0022131
27838489	1633	1638	HMGB1	T116,T123	C0019796
27838489	1642	1643	H	T046	C0242184
27838489	1646	1647	R	T061	C0087111
27838489	1657	1662	islet	T023	C0022131
27838489	1663	1669	injury	T037	C0178314
27838489	1722	1727	STAT3	T116,T123	C0253050
27838489	1739	1742	p38	T116,T126	C1120843
27838489	1757	1762	NF-κB	T116,T129	C0079904
27838489	1775	1780	HMGB1	T116,T123	C0019796
27838489	1781	1791	inhibition	T052	C3463820
27838489	1795	1809	ethyl pyruvate	T109,T121	C0208225
27838489	1813	1821	blockade	T169	C0332206
27838489	1838	1848	antibodies	T116,T129	C0003241
27838489	1877	1892	phosphorylation	T044	C1158886
27838489	1896	1901	STAT3	T116,T123	C0253050
27838489	1903	1906	p38	T116,T126	C1120843
27838489	1911	1915	IκBα	T116,T123	C0126732
27838489	1921	1931	production	T044	C0597295
27838489	1935	1940	IL-1β	T116,T129	C0021753
27838489	1945	1950	TNF-α	T116,T129	C1456820
27838489	1960	1965	islet	T023	C0022131
27838489	1966	1972	injury	T037	C0178314
27838489	1986	1992	islets	T023	C0022131
27838489	1999	2007	exposure	T080	C0332157
27838489	2011	2012	H	T046	C0242184
27838489	2015	2016	R	T061	C0087111
27838489	2044	2049	early	T079	C1279919
27838489	2050	2055	islet	T023	C0022131
27838489	2056	2069	graft failure	T046	C1262018
27838489	2102	2107	HMGB1	T116,T123	C0019796
27838489	2108	2116	released	T169	C0391871
27838489	2122	2123	H	T046	C0242184
27838489	2126	2127	R	T061	C0087111
27838489	2136	2142	islets	T023	C0022131
27838489	2155	2171	autocrine manner	T043	C3825249
27838489	2175	2186	up-regulate	T044	C0041904
27838489	2187	2191	STAT	T116,T123	C1366753
27838489	2195	2198	p38	T116,T126	C1120843
27838489	2211	2216	IL-1β	T116,T129	C0021753
27838489	2217	2227	production	T044	C0597295
27838489	2232	2236	TLR2	T116,T192	C0754728
27838489	2242	2253	up-regulate	T044	C0041904
27838489	2254	2259	NF-κB	T116,T129	C0079904
27838489	2272	2277	TNF-α	T116,T129	C1456820
27838489	2278	2288	production	T044	C0597295
27838489	2293	2297	TLR4	T116,T192	C1411976
27838489	2301	2312	intra-islet	T023	C0022131
27838489	2340	2341	H	T046	C0242184
27838489	2344	2345	R	T061	C0087111
27838489	2355	2360	islet	T023	C0022131
27838489	2361	2367	injury	T037	C0178314
27838489	2378	2391	graft failure	T046	C1262018